Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.57 |
| ▸ | CLK2 | P49760 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | NEK4 | P51957 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490812 | 1.00 | PIM1 (0.60) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL5486196 | 0.92 | PIM1 (0.60) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL5486192 | 0.92 | PIM1 (0.60) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL14492584 | 0.92 | PIM1 (0.60) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL7458015 | 0.89 | PIM1 (0.52) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL7458010 | 0.89 | PIM1 (0.52) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL7461962 | 0.89 | IGF1R (0.59) | PIM1PIM2PIM3PDE4BIGF1R | |
| SCHEMBL7461958 | 0.89 | IGF1R (0.59) | PIM1PIM2PIM3PDE4BIGF1R | |
| SCHEMBL7461652 | 0.89 | PIM1 (0.48) | PIM1PIM2PIM3PDE4BGSK3B | |
| SCHEMBL7461650 | 0.89 | PIM1 (0.48) | PIM1PIM2PIM3PDE4BGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | PIM1 2383/4885PIM2 1465/4885PIM3 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.